Scientists are excitedly examining retatrutide, a promising medication developed by Eli Lilly, as a significant step in physique reduction . Unlike many earlier approaches, retatrutide is a dual -action receptor targeting simultaneously GLP-1 and GIP, substances that influence satiety and blood